Browse the evidence

The position statement reviews current knowledge and gaps regarding exercise and management issues for athletes with diabetes.

This statement can guide healthcare professionals in addressing exercise-related concerns for diabetic athletes.

ADA/ISPAD goal achievement was associated with greater cardiopulmonary fitness, with VO2peak values significantly higher in those meeting more goals.

Practitioners should promote achieving ADA/ISPAD goals to enhance cardiopulmonary fitness in adolescents with type 1 diabetes.

This systematic evaluation provides evidence-based quantitative estimates of the effects of major dietary factors on CVD and diabetes.

Practitioners can rely on these estimates for understanding dietary impacts on health.

Ten days of low energy availability (LEA) resulted in impaired performance in trained females, with reductions in muscle glycogen content and physical performance parameters.

Athletes should be cautious about using low energy availability strategies as they may impair performance.

Maximizing exercise-induced muscle hypertrophy requires an energy surplus.

Practitioners should ensure that athletes are in a caloric surplus to optimize muscle growth.

Gains in muscle mass can be achieved under hypocaloric conditions.

While muscle gain is possible in a deficit, a surplus is recommended for optimal results.

Dietary energy intake and macronutrient ratios should be manipulated to optimize muscular adaptations.

Athletes should adjust their diet to enhance muscle growth effectively.

GLP-1 receptor agonists are effective agents for weight loss.

Practitioners can consider GLP-1 receptor agonists as a viable option for weight loss in patients.

Tirzepatide shows great efficacy in glycosylated hemoglobin and weight reduction.

Tirzepatide may be effective for improving glycemic control and promoting weight loss in diverse patient groups.

A 2-month very low energy diet (VLED) resulted in a reduction of waist circumference by 10.6 cm and total weight loss of 12.9 kg in obese patients with obstructive sleep apnea (OSA).

Implementing a VLED can lead to significant weight loss and waist circumference reduction in obese patients with OSA.

A structured weight loss maintenance program incorporating commonly used diets was feasible, tolerable, and efficacious for 10 months after rapid weight loss.

Practitioners can consider structured maintenance diets to support weight loss in OSA patients.

GLP-1 receptor agonists (GLP-1 RAs) have shown promising potential in promoting weight loss and preventing diseases associated with obesity.

GLP-1 RAs may be considered as a pharmacologic option for obesity treatment.

Semaglutide and liraglutide have been approved as weight loss medications due to their effectiveness in promoting significant and sustained weight loss.

Clinicians can prescribe semaglutide and liraglutide for weight management in eligible patients.

Weight loss can improve obesity-related comorbidities such as metabolic syndrome, diabetes, cardiovascular disease, and obstructive sleep apnea.

Weight loss should be emphasized in preoperative counseling for patients with obesity.

GLP-1 agonists resulted in a percentage of change in body weight of -6.2% at six months.

GLP-1 agonists may be an effective option for weight loss in obese IBD patients.

58.3% of patients achieved a weight reduction of 5% or more at six months.

A significant portion of obese IBD patients may benefit from GLP-1 agonist therapy for weight loss.

Semaglutide is effective for weight loss in obese or overweight patients.

Semaglutide can be considered as a treatment option for weight management in obese or overweight patients.

The study provides a comprehensive evaluation of the effects of semaglutide for obesity or overweight.

Clinicians can refer to this study for a balanced view of semaglutide's effects.

Incretin-based therapies resulted in significant reductions in body weight and/or body mass index in patients with obstructive sleep apnea.

Practitioners may consider incretin-based therapies as effective options for weight management in OSA patients.

Tirzepatide has demonstrated significant body weight reductions in individuals with obesity but not diabetes.

Tirzepatide may be beneficial for weight management in patients with obesity.

Performing cardiovascular exercise early in the morning on an empty stomach may enhance fat mobilization for fuel.

Practitioners may consider recommending morning cardio on an empty stomach for fat loss.

HU6 treatment for 19 weeks significantly decreased body weight by -2.86 kg compared to placebo (P = .003).

HU6 may be an effective treatment option for weight loss in patients with obesity-related HFpEF.

HU6 treatment significantly decreased total fat mass by -2.96 kg compared to placebo (P < .001).

HU6 may help reduce fat mass in patients with obesity-related HFpEF.

Recommendations for dietary guidelines should be expressed in terms of foods and not macronutrients.

Practitioners should focus on food-based dietary recommendations rather than macronutrient ratios.